We are interested in novel targets, innovative compounds and technologies that address unmet medical needs, and have the potential to be disease modifying, for people living with a serious chronic disease.

Partnerships based on long-term commitment and mutual interest, and open innovation platforms that share knowledge and data, are key to fostering this innovation.

From universities and biotech companies worldwide, to individual scientists and entrepreneurs, our ability to meet our goals depends on working with you.

There are millions of people living with a serious chronic disease relying on us. 


  • Industry leading capabilities in developing, manufacturing, and commercialising biological therapies.
  • Sustainable and trust-based relationships, with  bespoke engagement models and deal terms.

  • Pipeline partners to develop innovative products that resolve unmet medical needs.
  • Commercial partners to make our products accessible to patients around the world.  

We take part in public-private partnerships where they offer an opportunity to help people living with a  serious chronic disease.

One example is our involvement in a new European collaborative research project Hypo-RESOLVE - an international consortium of experts from academia, industry and civil society. The project aims to provide evidence-based insights into all aspects of hypoglycaemia to better understand its impact on people living with diabetes.

Collaborations with external partners are essential to our R&D efforts. We constantly seek new partnerships with leading individual experts and research teams within biotechnology, academia, as well as with other pharmaceutical companies.

We are always interested in gaining access to the latest relevant innovation and research, and we regularly license intellectual property rights to new technologies or assets from leading external partners. License agreements can be structured in many ways, but our objective is always to expand our pipeline with new exciting assets and/or to support projects with critical technologies

We will also consider the acquisition of small start-ups or parts of biotech companies in cases where there is a good match in complementary expertise and mutual interest.